

The Board of Directors' statement under Chapter 19, Section 22 of the Swedish Companies Act

The Board of Directors has proposed that the annual general meeting to be held on 31 May 2024 resolves to authorize the Board of Directors to purchase up to 10,572,577 C-shares. The Board of Directors considers, in view of what is stated below, that the resolution to acquire own shares is justifiable with respect to the requirements that the business' nature, scale and risk place on the amount of equity, as well as the need for Oncopeptides AB (publ) to strengthen the balance sheet, liquidity and position as a whole. The Board of Directors has also taken into account the requirements of the group's business, scope and risk place on the group's equity requirement and need for the group to strengthen its balance sheet, liquidity and position as a whole.

Equity

The Board of Directors considers that the equity of Oncopeptides AB (publ) will be of sufficient amount after the proposed acquisitions, taking into account the business' nature, scale and risk that the business is associated with and the current economic situation, historical development and forecasts for Oncopeptides AB (publ) as well as for the market.

Need of strengthening of the balance sheet, liquidity and position as a whole

The Board of Directors has made a comprehensive assessment of Oncopeptides AB (publ)'s financial position and its ability to, in the long term, fulfil its undertakings. As stated in Oncopeptides AB (publ)'s annual report for the financial year 2023, the non-restricted equity of Oncopeptides AB (publ)'s as per 31 December 2023 was TSEK 39,449.

The proposed acquisitions of shares do not affect Oncopeptides AB (publ)'s ability to in due time fulfil its present and anticipated financial obligations or Oncopeptides AB (publ)'s ability to implement planned investments.

The Board of Directors has also considered other known matters that may affect Oncopeptides AB (publ)'s financial position and that have not been considered within the scope of the above mentioned. No other matter that would make the proposed acquisitions unjustifiable has been identified during such analysis.

Stockholm, April 2024

Oncopeptides AB (publ)

The Board of Directors